Naperville-based Alive Center for Teens to start franchising
But then they discovered the Alive Center for Teens in Naperville. The sense of comfort Bauer felt was immediate, they said.
'I completely fell in love with Alive,' said Bauer, who graduated from Metea Valley High School over the weekend. 'You're immediately welcomed with open arms.'
Now, Alive is looking to expand its reach.
The nonprofit is ready to start franchising, the center has announced. With locations in Naperville, Aurora and Hanover Park, the organization has launched a social franchise model and is hoping to 'significantly expand its proven teen support system statewide,' the release said.
'That's really the message we're (giving) out, that we're here,' said Kandice Henning, CEO of The Alive Center. 'That we have a solution that is proven and works and we are willing to share it. We really want to help more kids and impact more kids in a positive way. (We want to) help more families and more communities ultimately.'
The Alive Center opened in 2015. Designed for students in fifth through 12th grade, it offers free school and summer programming spanning a wide range of subjects and focus areas, including leadership, nutrition, stress management, meditation and creative expression, among others. It also offers free tutoring services.
At the core of the center's mission is to create the 'confident, impassioned and resilient leaders of tomorrow,' according to its website. As part of that vision, the nonprofit has a 20- to 30-member Teen Advisory Board that gives youth the opportunity to try their hand at leading their own initiatives and projects.
On the whole, the aim is 'preventative mental health care,' Henning said.
In last year's Illinois Youth Survey, 27% of DuPage County 10th- and 12th-graders said over a 12-month period, they had felt 'so sad or hopeless almost every day for two weeks or more in a row' that they stopped doing some usual activities. The Illinois Youth Survey is a self-report survey administered in school settings across the state every other year. The Illinois Department of Human Services has funded the administration of the survey since 1990.
'It's all about protective factors. … (It's about giving them) a space to be safe,' Henning said, 'and to feel where they belong because the (Centers for Disease Control and Prevention) says the number one thing that helps with positive mental health in youth and adults is connection.'
Franchising Alive's method has been a long time coming. The idea grew out of the B.R. Ryall YMCA in Glen Ellyn approaching the nonprofit three years ago about wanting to establish a franchise, Henning said. Originally, Alive's intent had been to work with the YMCA to do just that.
Ultimately, though, the Glen Ellyn facility instead ended up becoming certified by the Alive Center to take a teen-driven approach to programming rather than building out a full-blown franchise. But by that point, the Alive Center had already started creating the materials necessary to facilitate franchising, Henning said.
Initially, the Alive Center plans to focus on potential franchisees in Illinois, specifically the Chicago metropolitan area. Franchisees could include someone wanting to build out a new standalone center or a 'fractional franchise' as part of an already existing entity, Henning said. For the latter, she used the example of a Target offering a Starbucks franchise inside its store.
In the case of the Alive Center, a fractional franchise could look like a center integrated into a library or park district, or even a municipal building, she said.
Long-term, franchising will allow the Alive Center to grow faster, Henning said.
'If we went (with) the model of satellites … we might be able to do one a year but probably more likely one every two years,' she said. 'A franchise model enables us to do this much more quickly because it's not all on us.'
Franchisees will have access to training, consulting, standardized processes and procedures, customizable templates and ongoing collaborative support, according to Alive.
Since its inception eight years ago, the Alive Center has recorded more than 85,000 teen visits, serving more than 8,000 teens.
If it wasn't for the Alive Center, Bauer said, 'I truly don't think that I would be in a good headspace now.'
Post graduation, Bauer plans to attend College of DuPage for the next two years and after that transfer to Illinois State University. They want to be a teacher.
tkenny@chicagotribune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
a few seconds ago
- Indianapolis Star
A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials
SHELTON, CONNECTICUT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials. Recently, increase in inflammation, and particularly the cytokine IL-6, caused by viral infections has been found to be linked to an increased risk of resurgence of metastatic cancer, in a study of COVID-19 (SARS-CoV-2 infection) and breast cancer, as well as Influenza virus infections and cancer [1] . This study has further substantiated that viral infections can lead to resurgence of metastatic cancers by re-activating 'sleeping' cancer cells. 'NV-387 is a remarkable antiviral drug, in that it not only attacks the virus, but also reduces inflammation, calming the human immune system so that untoward effects do not take place,' said Anil R. Diwan, Ph.D., President and Chairman of the Company, adding, 'We have found that NV-387 treatment reduces inflammation markers, particularly, IL-6, thereby protecting lungs. This reduction in inflammation and cyto-protective effect of NV-387 would also help minimize the risk of reawakening cancer, based on these reported studies.' Thus NV-387 treatment could have a strong impact in the treatment of cancer patients in remission who suffer from a viral infection that could lead to the cancer returning with metastasis to multiple sites in the body. COVID-19 has become endemic globally, with generally two waves every year. The summer surge is already occurring in the USA, with approximately 4,000 hospitalizations per week in the week ending July 26 at the beginning of the surge, fueled by ever-changing variants [2] . Influenza virus is a well-known endemic virus that causes pandemics globally. RSV is an endemic virus that causes particularly severe diseases in infants and children as well as adults. Measles virus causes 'immune system amnesia' and is increasing globally. NV-387 is the only antiviral drug that has been uniquely found to be effective in the treatment of lethal lung viral infections caused by all of these viruses in animal model studies that are predictive of human clinical effectiveness. This clearly demonstrates the unmet medical need for NV-387, a broad-spectrum antiviral that the viruses cannot escape even as new variants are created. In contrast, antibodies and vaccines readily fail with new variants arising, as is now well known. NV-387 treatment has been found to reduce the level of IL-6 in lethal viral infections causing lung diseases in animal models. Excellent protection of lungs was found to occur in NV-387-treated animals but not in ribavirin treated animals in a lethal RSV infection study. Strong protection of lungs was found to occur in NV-387-treated animals in a lethal lung-infection of Influenza A/H3N2 study. In this Influenza study, the approved drugs Tamiflu (oseltamivir), Rapivab (peramivib), and Xofluza (baloxavir) failed to protect the lungs of animals to any appreciable extent, indicating the superiority and clinical viability of NV-387. The Company further investigated the extra-ordinary effect of NV-387 on protection of lungs in lethal viral infections. Reduction in inflammatory cytokines, particularly IL-6, was found to occur to an appreciable extent in NV-387 treated animals. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ [1] Publication: 'Respiratory viral infections awaken metastatic breast cancer cells in lungs', Chia et al, J DeGregori group, [2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. SOURCE: NanoViricides, Inc. View the original press release on ACCESS Newswire The post A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials appeared first on DA80 Hub.
Time Magazine
3 hours ago
- Time Magazine
Public Health Workers Criticize RFK Jr. After CDC Shooting
More than 750 public health workers sent a letter to Health Secretary Robert F. Kennedy Jr. on Wednesday, urging him to 'stop spreading inaccurate health information' and guarantee employees' safety, in the wake of a shooting at the headquarters of the Centers for Disease Control and Prevention (CDC) earlier this month. The letter—signed by both named and anonymous current and former staffers at the U.S. Department of Health and Human Services (HHS), CDC, and National Institutes of Health who noted they signed the letter in their 'own personal capacities'—said the attack on the CDC's headquarters in Atlanta on Aug. 8 'was not random.' 'The attack came amid growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization—and now, violence,' public health workers said in the letter, which was also addressed to members of Congress. 'CDC is a public health leader in America's defense against health threats at home and abroad. When a federal health agency is under attack, America's health is under attack. When the federal workforce is not safe, America is not safe.' The public health workers went on to accuse Kennedy, a prominent vaccine skeptic, of being 'complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information.' They cited several statements and actions that Kennedy has made in recent months, pointing to his claim that mRNA vaccines 'fail to protect effectively' against upper respiratory infections such as COVID-19—despite years of research showing that the shots are both safe and effective—and his announcement that HHS would be winding down mRNA vaccine development. They also condemned his decision to remove all the experts from a critical vaccine advisory committee. And they said some of Kennedy's past comments—such as claiming that there is a 'cesspool of corruption at CDC'—were 'sowing public mistrust' in the health agency. The public health workers expressed their wish to honor police officer David Rose, who was killed while responding to the attack on the CDC headquarters in August. HHS said in a statement to TIME that Kennedy 'is standing firmly with CDC employees—both on the ground and across every center—ensuring their safety and well-being remain a top priority.' The agency added that, after the shooting earlier this month, Kennedy traveled to Atlanta and called the CDC 'a shining star' among the world's health agencies. 'For the first time in its 70-year history, the mission of HHS is truly resonating with the American people—driven by President Trump and Secretary Kennedy's bold commitment to Make America Healthy Again,' HHS said. 'Any attempt to conflate widely supported public health reforms with the violence of a suicidal mass shooter is an attempt to politicize a tragedy.' Law enforcement officials said they found evidence that the suspect in the August shooting, who they identified as Patrick Joseph White of Georgia, blamed the COVID-19 vaccine for his health ailments. White was found dead at the scene, and authorities later said that he died of a self-inflicted gunshot wound. CDC Director Susan Monarez noted the dangers posed by misinformation in a staff meeting in the wake of the attack. 'We know that misinformation can be dangerous,' she said, according to NBC News. 'Not only to health, but to those that trust us and those we want to trust. We need to rebuild the trust together.' The day after the shooting, Kennedy expressed his condolences to Rose's family in a post on X. 'We know how shaken our public health colleagues feel today. No one should face violence while working to protect the health of others,' he said. 'We are actively supporting CDC staff on the ground and across the agency. Public health workers show up every day with purpose—even in moments of grief and uncertainty. We honor their service. We stand with them. And we remain united in our mission to protect and improve the health of every American.' Kennedy was one of President Donald Trump's most controversial Cabinet nominees, and faced heated questioning by Senators during his confirmation hearings. He has drawn outrage from the medical establishment in the past for spreading disinformation, including repeating the debunked claim that vaccines cause autism. In their letter, public health workers claimed Kennedy's 'dangerous and deceitful statements and actions have contributed to the harassment and violence experienced by CDC staff.' They implored him to take three steps by Sept. 2 to 'uphold his pledge to safeguard the health of the American public,' including asking him to 'stop spreading inaccurate health information,' particularly regarding vaccines, infectious disease transmission, and the country's public health institutions. They also urged him to affirm the scientific integrity of the CDC and guarantee the safety of HHS employees, such as through emergency procedures and alerts. 'The deliberate destruction of trust in America's public health workforce puts lives at risk,' they wrote in the letter. 'We urge you to act in the best interest of the American people—your friends, your families, and yourselves.'
Yahoo
4 hours ago
- Yahoo
Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.
It's late August, there's a hurricane coming up the East Coast, schools are starting to open, and no one has any idea who can get an updated Covid-19 shot. It has killed up to 56,000 people in the U.S. since last October, according to the Centers for Disease Control and Prevention, and sickened up to 18 million. Pfizer Moderna and Novavax all plan to launch new versions of their Covid-19 vaccines this fall, updated to target a family of Covid-19 viruses called JN.1.
